IGC Pharma, Inc. (IGC)Healthcare | Biotechnology | Potomac, United States | NYSE American
0.32 USD
-0.02
(-5.031%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:23 p.m. EDT
IGC Pharma is a high-risk biotech play awaiting a clinical binary (CALMA study) with deteriorating fundamentals (revenue down 53%, negative operating cash flow). While analysts project a move to $4.12 based on trial success, the current data shows no operational traction. Short-term momentum is weak, and without immediate proof of the Alzheimer's data, the balance sheet carries significant near-term downside risk. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.045194 |
| AutoETS | 0.046333 |
| AutoTheta | 0.083409 |
| AutoARIMA | 0.178321 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.327 |
| Excess Kurtosis | -1.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.804 |
| Revenue per Share | 0.013 |
| Market Cap | 31,515,952 |
| Forward P/E | -3.75 |
| Beta | 0.31 |
| Previous Name | India Globalization Capital, Inc. |
| Website | https://igcpharma.com |
As of April 18, 2026, 10:23 p.m. EDT: Options markets show extreme bearish positioning with Put IV at 58.0% versus a Call ATM IV of 1.94% for near-term expiry. Call volume is concentrated on $0.50 strikes (OTM relative to current $0.33 price), while Put activity is sparse and capped at $0.50 and $5.00 strikes. The massive disparity in implied volatility indicates speculators are pricing in a binary, high-x downside risk scenario, despite lack of significant OTM call writing from buyers.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.10344827 |
| Address1 | 10,224 Falls Road |
| All Time High | 71.1 |
| All Time Low | 0.14 |
| Ask | 0.3213 |
| Ask Size | 600 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 4,087,690 |
| Average Daily Volume3 Month | 957,422 |
| Average Volume | 957,422 |
| Average Volume10Days | 4,087,690 |
| Beta | 0.308 |
| Bid | 0.3055 |
| Bid Size | 300 |
| Book Value | 0.088 |
| City | Potomac |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.319 |
| Current Ratio | 1.324 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.331 |
| Day Low | 0.2949 |
| Debt To Equity | 1.804 |
| Display Name | IGC Pharma |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,424,000 |
| Ebitda | -7,524,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.807 |
| Enterprise To Revenue | 25.896 |
| Enterprise Value | 28,640,968 |
| Eps Current Year | -0.09 |
| Eps Forward | -0.085 |
| Eps Trailing Twelve Months | -0.06 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.2786 |
| Fifty Day Average Change | 0.0404 |
| Fifty Day Average Change Percent | 0.14501075 |
| Fifty Two Week Change Percent | 10.344828 |
| Fifty Two Week High | 0.5 |
| Fifty Two Week High Change | -0.181 |
| Fifty Two Week High Change Percent | -0.362 |
| Fifty Two Week Low | 0.24 |
| Fifty Two Week Low Change | 0.07900001 |
| Fifty Two Week Low Change Percent | 0.3291667 |
| Fifty Two Week Range | 0.24 - 0.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,148,477,400,000 |
| Float Shares | 83,429,113 |
| Forward Eps | -0.085 |
| Forward P E | -3.7529411 |
| Free Cashflow | -2,521,375 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 70 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.46203 |
| Gross Profits | 511,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09807 |
| Held Percent Institutions | 0.22758 |
| Implied Shares Outstanding | 98,796,089 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.indiaglobalcap.com/stockprice.php |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Last Split Date | 1,366,329,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland. |
| Long Name | IGC Pharma, Inc. |
| Market | us_market |
| Market Cap | 31,515,952 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_22356580 |
| Most Recent Quarter | 1,759,190,400 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -6,446,000 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 33,185,606 |
| Number Of Analyst Opinions | 2 |
| Open | 0.329 |
| Operating Cashflow | -5,544,000 |
| Operating Margins | -15.17801 |
| Payout Ratio | 0.0 |
| Phone | 301 983 0998 |
| Pre Market Change | -0.0021999776 |
| Pre Market Change Percent | -0.68986446 |
| Pre Market Price | 0.3167 |
| Pre Market Time | 1,776,764,829 |
| Prev Name | India Globalization Capital, Inc. |
| Previous Close | 0.3359 |
| Price Eps Current Year | -3.5444443 |
| Price Hint | 4 |
| Price To Book | 3.625 |
| Price To Sales Trailing12 Months | 28.495436 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.787 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0169 |
| Regular Market Change Percent | -5.03126 |
| Regular Market Day High | 0.331 |
| Regular Market Day Low | 0.2949 |
| Regular Market Day Range | 0.2949 - 0.331 |
| Regular Market Open | 0.329 |
| Regular Market Previous Close | 0.3359 |
| Regular Market Price | 0.319 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 35,431,023 |
| Return On Assets | -0.50312 |
| Return On Equity | -0.83341 |
| Revenue Growth | -0.536 |
| Revenue Per Share | 0.013 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 98,796,089 |
| Shares Percent Shares Out | 0.0075 |
| Shares Short | 742,667 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 675,735 |
| Short Name | IGC Pharma, Inc. |
| Short Percent Of Float | 0.013300001 |
| Short Ratio | 2.55 |
| Source Interval | 15 |
| State | MD |
| Symbol | IGC |
| Target High Price | 5.25 |
| Target Low Price | 3.0 |
| Target Mean Price | 4.125 |
| Target Median Price | 4.125 |
| Total Cash | 1,130,000 |
| Total Cash Per Share | 0.012 |
| Total Debt | 146,000 |
| Total Revenue | 1,106,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.33725 |
| Two Hundred Day Average Change | -0.018249989 |
| Two Hundred Day Average Change Percent | -0.054114126 |
| Type Disp | Equity |
| Volume | 35,431,023 |
| Website | https://igcpharma.com |
| Zip | 20,854 |